Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Support
This activity is supported by an educational grant from Pfizer Inc.
Medical Crossfire®: Evidence-Based Approaches to Improve Outcomes in BRAF V600E–Mutated Colorectal Cancer
Release Date: August 14, 2020
Expiration Date: August 14, 2021
The Medical Crossfire®, one of PER®'s signature educational formats, is a video-based program in which a panel of distinguished experts engage in discussions on a particular clinical topic. In this activity, 4 key thought leaders explore the optimal testing approaches for identifying the various biomarkers in metastatic colorectal cancer (mCRC), with particular focus on the BRAF V600E mutation, and the role of biomarkers in making treatment decisions. The discussion also focuses on recent data from clinical trials of current and emerging agents for the treatment of patients with mCRC. This lively discussion will help place new developments into clinical context to help optimize care for patients with mCRC.
Acknowledgement of Commercial Support
This activity is supported by an educational grant from Pfizer Inc.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate.
This educational program is directed toward medical oncologists, surgeons, and pathologists interested in the diagnosis, treatment, and management of colorectal cancer. Other allied health care professionals involved in the treatment and management of patients with colorectal cancer will also be invited to participate.
Upon successful completion of this activity, you should be better prepared to:
- Discuss the prevalence of BRAF mutations and appropriate biomarker testing for CRC
- Evaluate recently reported data regarding safety and efficacy of emerging treatment options for CRC
- Integrate recent data and current treatment guidelines in the management of patients with advanced CRC
- Identify appropriate management strategies for adverse events associated with therapeutic options used to treat patients with BRAF-mutated CRC
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Professor, Mayo Clinic College of Medicine and Science
Leader, Gastrointestinal Cancer Program
Mayo Clinic Cancer Center
Chair, ACCRU Research Consortium
Disclosures :Research Funding (to institution): Boston Biomedical, Bayer, Amgen, Merck, Celgene, Lilly, Ipsen, Clovis Oncology, Seattle Genetics, Array BioPharma, Genentech, AbGenomics, Incyte, Bristol Myers Squibb; Consulting (to institution): Ipsen, Array BioPharma, Seattle Genetics, Bayer, Genentech, Incyte, Merck; Consulting (to self): Boehringer Ingelheim, Janssen, Eisai, Daiichi Sankyo, Natera, Treos Bio, Sobi; IDMC/DSMB (to self): AstraZeneca, Exelixis, Lilly, PanCAN, 1Globe Health Institute; Scientific Advisory Board: Imugene, Immuneering, Sun BioPharma; Other: Inventions/Patents: WO/2018/183488 and WO/2019/055687.
Chief, Division of Hematology/Oncology
Medstar Georgetown University Hospital
Director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer
Georgetown University Medical Center
Disclosures: Grant/Research Support: Genentech, Bayer, Taiho Pharmaceutical, Celgene, Caris Life Sciences, Ipsen, Indivumed, Merck; Consultant: Genentech, Bayer, Taiho Pharmaceutical, Celgene, Caris Life Sciences, Ipsen, Indivumed, Merck; Speakers Bureau: Genentech, Bayer, Taiho Pharmaceutical, Celgene, Caris Life Sciences, Ipsen, Merck.
Chief Development Officer
Director, Drug Development Unit Nashville
Sarah Cannon Research Institute
Disclosures: Grant Research Support (to Institution): Gilead, Genentech/Roche, Bristol Myers Squibb, Five Prime Therapeutics, Lilly, Merck, MedImmune, Celgene, EMD Serono, Taiho Pharmaceutical, MacroGenics, GSK, Novartis, OncoMed, Leap Therapeutics, TG Therapeutics, AstraZeneca, Boehringer lngelheim, Daiichi Sankyo, Bayer, Incyte, Apexigen, Kolltan Pharmaceuticals, SynDevRx, Forty Seven, AbbVie, Array BioPharma, Onyx Pharmaceuticals, Sanofi, Takeda, Eisai, Celldex Therapeutics, Agios, CytomX Therapeutics, Nektar, ARMO BioSciences, Boston Biomedical, Ipsen, Merrimack Pharmaceuticals, Tarveda Therapeutics, Tyrogenex, OncoGenex, Marshall Edwards, Pieris Pharmaceuticals, Mersana Therapeutics, Calithera, Blueprint Medicines, Evelo Biosciences, Forma Therapeutics, Merus, Jacobio Pharmaceuticals, eFFECTOR Therapeutics, NovoCare, Arrys Therapeutics, TRACON Pharmaceuticals, Sierra Oncology, Innate Pharma, Arch Oncology, Prelude Therapeutics, Unum Therapeutics, Vyriad, Harpoon Therapeutics, ADC Therapeutics, Amgen, Pfizer, Millennium Pharmaceuticals, lmClone Systems, Acerta Pharma, Rgenix, Bellicum, Gossamer Bio, Arcus Biosciences, Seattle Genetics, Tempest Therapeutics, Shattuck Labs, Synthorx, Revolution Medicines, Bicycle Therapeutics, Zymeworks, Relay Therapeutics, Scholar Rock, NGM Bio, Stemcentrx, BeiGene, CALGB, Cyteir Therapeutics, Foundation Medicine, Innate Pharma, Morphotex, Oncologie, Numab Therapeutics; Consultant/Advisory Role (to institution): Gilead, Genentech/Roche, Bristol Myers Squibb, Five Prime Therapeutics, Lilly, Merck, MedImmune, Celgene, Taiho Pharmaceutical, MacroGenics, GSK, Novartis, OncoMed, Leap Therapeutics, TG Therapeutics, AstraZeneca, Boehringer lngelheim, Daiichi Sankyo, Bayer, lncyte, Apexigen, Array BioPharma, Sanofi, ARMO BioSciences, Ipsen, Merrimack Pharmaceuticals, OncoGenex, Forma Therapeutics, Arch Oncology, Prelude Therapeutics, PhoenixBio, Cyteir Therapeutics, Molecular Partners, Innate Pharma, Torque, Tizona Therapeutics, Janssen, Tolero Pharmaceuticals, TD2 (Translational Drug Development), Amgen, Seattle Genetics, Moderna, Tanabe Research Laboratories, BeiGene, Continuum Clinical, Agios, Bicycle Therapeutics, Relay Therapeutics, Evelo, Pfizer, Piper Biotech, Samsung Bioepis; Other: Food/Beverage/Travel (to institution): Gilead, Genentech/Roche, Bristol Myers Squibb, Lilly, Merck, MedImmune, Celgene, Taiho Pharmaceutical, Novartis, OncoMed, Boehringer lngelheim, ARMO BioSciences, Ipsen, OncoGenex, Forma Therapeutics.
Professor, Department of Pathology
Division of Pathology/Lab Medicine
The University of Texas MD Anderson Cancer Center
Disclosures: Dr Dipen Maru has no relevant financial relationships with commercial interests to disclose.
The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.